Patients & Caregivers
Blastic Plasmacytoid Dendritic Neoplasm Study Begins for CAR T-Cell Candidate
A Phase 1 clinical study testing CAR T-cell therapy, UCART123,to treat blastic plasmacytoid dendritic cell neoplasm at the MD Anderson Cancer Center has begun.
Glioblastoma Treatment Gets FDA Orphan Drug Designation
Curtana announced the FDA has granted CT-179 with an Orphan Drug Designation to treat for gliomas, including glioblastoma in adults and brain tumors in children.
FDA Approves Ovarian Cancer Treatment
The FDA approved olaparib tablets (Lynparza) for adult patients with recurrent epithelial ovarian fallopian tube, or primary peritoneal cancer.
FDA Approves Pfizer Drug for Acute Lymphoblastic Leukemia
FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor ALL
GI Problems Common in Neurofibromatosis Type 1
NF-1 patients often suffer from chronic constipation that can greatly impact their health and quality of life.
Two Potential Hepatocellular Carcinoma Treatments Get Orphan Drug Designations
Singapore-based clinical-stage biotechnology company Lion TCR was granted 2 orphan drug designations today by the U.S. Food and Drug Administration (FDA) for T-cell therapies.
Data Not Promising for CA4P to Treat Ovarian Cancer
Interim analysis of a Phase 2/3 study testing CA4P in platinum-resistant ovarian cancer patients is struggling to meet its primary endpoint.
Clinical Hold Lifted for Head and Neck Cancer Study
Head and neck cancers begin in the mouth, nose, throat, larynx, sinuses, or salivary glands. Most are squamous cell carcinomas.
Acute Myelogenous Leukemia Treatment Gets Orphan Drug Designation
H3B-8800, was granted orphan drug designation by the FDA for the treatment of patients with acute myeloid leukemia, and chronic myelomonocytic leukemia.
Twin Saves Sister from Rare Cancer with Radical Procedure
Mariann's plexiform fibrohistiocytic sarcoma had taken over most of her back. Her treatment required a donor that was compatible.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
RARE DISEASE INFOGRAPHIC >
CONDITION CENTERS >
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Intellisphere, LLC. All Rights Reserved.